Understanding Parkinson’s Disease: A Personal and Professional View

Understanding Parkinson’s Disease: A Personal and Professional View

Volumn , Issue , 2006, Pages 1-249

  Rosenbaum, Richard B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880251816     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (97)

1. Parkinson J. An Essay on the Shaking Palsy . London: Sherwood, Neely, and Jones; 1817:1, 5.
2. Charcot JM. On paralysis agitans. In: Leçons sur les maladies du système nerveux. Paris: Delehaye; 1872/1973:105–128.
3. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
4. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study. Neurology. 1992;42:1142–1146.
5. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression, and mortality. Neurology. 1967;17:427–442.
6. Cotzias GC, VanWoert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. New Engl J Med. 1967;276:374–379.
7. Gancher S. Scales for the assessment of movement disorders. In: Herndon R, ed. Handbook of Neurologic Rating Scales . 1st ed. New York: Demos Vermande; 1997:81–106.
8. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q 10 in early Parkinson disease: Evidence of slowing of functional decline. Arch Neurol. 2002;59:1541–1550.
9. Parkinson J. An Essay on the Shaking Palsy . London: Sherwood, Neely, and Jones; 1817:i.
10. Golgi C. The neuron doctrine—Theory and facts. In: The Nobel Lectures, Physiology or Medicine, 1901–1921. Amsterdam: Elsevier; 1967:189–217. Available at: http://www.nobel.se/medicine/laureates. AccessedApril 1, 2006.
11. Ramón y Cajal S. The structure and connexions of neurons. In: The Nobel Lectures, Physiology or Medicine, 1901–1921. Amsterdam: Elsevier; 1967:220–253. Available at: http://www.nobel.se/medicine/laureates.Accessed April 1, 2006.
12. Ramón y Cajal S. Recollections of My Life. Philadelphia, PA: American Philosophical Society; 1937: 324.
13. Tello Valdivieso F. Some aspects of Cajal’s personality. In: Grisolía S, Guerri C, Samson F, Norton S, Reinoso-Suárez F, eds. Ramón y Cajal’s Contribution to the Neurosciences. Amsterdam: Elsevier; 1983:23–27.
14. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci. 1987;10:19–40.
15. Carlsson A. Lecture at Oregon Health and Sciences University. October 9, 2002.
16. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia—Normal and in Parkinson’s disease. J Chem Neuroanat. 2001;22:3–12.
17. Birkheimer H, et al. Brain dopamine and the syndrome of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–455.
18. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson’s disease? J Neurol Neurosurg Psychiatry. 1996;61:4–16.
19. Snow J. On the Mode of Communication of Cholera. London: John Churchill; 1856:38. Available at: http://www.ph.ucla.edu/epi/snow.html(an excellent Web site that reviews Snow’s contribution to epidemiology).Accessed July 8, 2006.
20. Kumar A, Calne SM, Schulzer M, et al. Clustering of Parkinson disease: Shared cause of coincidence? Arch Neurol. 2004;61:1057–1060.
21. Stone R. Parkinson’s disease: Coincidence or connection? Science. 2002;296:451–452.
22. Hill AB. The environment and disease: Association or causation? Proc. R. Soc. Med. 1965;58:295–300.
23. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study. Neurology. 2000;55:1350–1358.
24. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50:1346–1350.
25. Williams DB, Annegers JF, Kokmen E, O’Brien PC, Kurkland LT. Brain injury and neurologic sequelae: A cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology. 1991;41:1554–1557.
26. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: A case-control study. Neurology. 2003;60:1611–1615.
27. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson’s syndrome: Evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis. 1963;16:961–973.
28. Rail D, Scholtz C, Swash M. Post-encephalitic Parkinsonism: Current experience. J Neurol Neurosurg Psychiatry. 1981;44:670–676.
29. Schwab RS, Poskanzer DC, England AC Jr, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168–1170.
30. Langston WJ, Ballard P, Tetrud JW, and Irwin I. Chronic parkinsonism in humans due to a product of mederidine-analog synthesis. Science. 1983;219:979–980.
31. Langston JW, Palfreman J. The Case of the Frozen Addicts. New York: Vintage Books; 1996.
32. Davis GC, Williams AC, Markey SP, Ebert H, Caine ED, Reichert CM, Kopin IJ. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979;1:249–254.
33. Huntington G. On chorea. Med Surg Rep. 1872;26:317–321.
34. Wexler A. Mapping Fate: A Memoir of Family, Risk, and Genetic Research. Berkeley: University of California Press; 1999.
35. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New Engl J Med. 1996;334:71–76.
36. Langston JW, Palferman J. The Case of the Frozen Addicts. New York: Vintage Book; 1996:126
37. Ward CD, et al. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815–824.
38. Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK. Parkinson’s disease in a nationwide twin cohort. Neurology. 1988;38:1217–1219.
39. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol. 1990;27:276–282.
40. Golbe LI, Di Iorio G, Sanges G, Lazzarini AM, La Sala S, Bonavita V, et al. Clinical genetic analysis of Parkinson’s disease in the Contursi kindred. Ann Neurol. 1996;40:767–775.
41. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science. 1996;274:1197–1199.
42. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identifi ed in families with Parkinson’s disease. Science. 1997;276:2045–2047
43. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451–452.
44. Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, et al. Gaucher’s disease with Parkinson’s disease: Clinical and pathological aspects. Neurology. 2003;61:99–101.
45. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. New Engl J Med. 2004;351:1972–1977.
46. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliata M, Hunt AL, Klein C, and Henick B. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. New Engl J Med. 2006;354:424–425.
47. Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger A-L, Janin S, Pollak P, Brice A. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. New Engl J Med. 2006;354:422–423.
48. Vaidya AB, Rajagopalan TG, Manoki NA, et al. Treatment of Parkinson’s disease with the cowhedge plant— Mucuna pruriens Bak. Neurol India. 1978;26:171–176.
49. Damodaran M, Ramaswamy R. Isolation of L-dopa from the seeds of Mucuna pruriens. Biochemistry. 1937;31:2149–2151.
50. Chan K. Jimson weed poisoning: A case report. Permanente J. 2002;6(4):28–30. Available at: http://xnet.kp.org/permanentejournal/fall02/Fall02.pdf. Accessed July 8, 2006. Italicized text added
51. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson’s disease. Neurology. 2001;57:790–794.
52. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. Heavy metal content of Ayurvedic herbal medicine products. JAMA. 2004;292:2868–2873.
53. Fontanarosa PB, Lundberg GD. Alternative medicine meets science. JAMA. 1998;280:1618–1619.
54. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. New Engl J Med. 1967;276:374–379.
55. Birkmayer W, Hornykiewicz O. Der L-Dioxyphenylalanin (= Ldopa)—Effeckt beim der Parkinson-Akinese. Wien Klin Wochenschr. 1961;73:787–788
56. Deniker P. From chlorpromazine to tardive dyskinesia (brief history of neuroleptics). Psychiatr J Univ Ottawa. 1989;14:253–259.
57. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy from the addition of L-deprenyl to Madopar treatment in Parkinson’s disease: A longterm study. J Neural Transm. 1985;64:113–127.
58. Parkinson Study Group. Effects of tocopherol and deprenyl of the progression of disability in early Parkinson’s disease. New Engl J Med. 1993;328:176–183.
59. Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, et al. Investigation by Parkinson’s Disease Research Group of the United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: Further results of randomised trial and confi dential inquiry. BMJ. 1998;316:1191–1196.
60. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q 10 in early Parkinson disease: Evidence of slowing of functional decline. Arch Neurol. 2002;59:1541–1550.
61. Pure Prescriptions Web site. Available at: http://www.pureprescriptions.com. Accessed April 1, 2006.
62. Zhang J, Qu FR, Nakatsuka A, Nomura T, Nagai M, Nomoto M. Pharmacokinetics of L-dopa in plasma and extracellular fl uid of striatum in common marmosets. Brain Res. 2003;993:54–58.
63. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. New Engl J Med. 2000;342:1484–1491.
64. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson’s disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–582.
65. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol. 2001;50:34–41.
66. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93–101.
67. Sacks O. Awakenings. New York: Harper Collins; 1990:375–386.
68. Double K, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A, et al. Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol. 2003;60:545–549.
69. Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson’s disease: A historical perspective. Mov Disorders. 1998;12:582–588.
70. Meyers R. Historical background and personal experiences in the surgical relief of hyperkinesia and hypertonus. In: Fields WS, ed. Pathogenesis and Treatment of Parkinsonism. Springfield, IL: Charles C. Thomas; 1958:229–270.
71. Axelrod L. Bones, stones and hormones: The contributions of Fuller Albright. New Engl J Med. 1970;283:964–970.
72. Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deepbrain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. New Engl J Med. 2001;345:956–963.
73. Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson’s disease. New Engl J Med. 1987;316:831–834.
74. Taylor JR, Elsworth JD, Roth RH, Sladek JR Jr, Collier TJ, Redmond DE Jr. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: A comparison with other types of grafts as controls. Exp Brain Res. 1991;85:335–348.
75. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl J Med. 1992;327:1556–1563.
76. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. New Engl J Med. 2001;344:710–719.
77. Brill IC, Rosenbaum WM, Rosenbaum EE, Flanery JR. Internal mammary ligation. Northwest Med. 1958;57:483–486.
78. Bakay RAE. Is transplantation to treat Parkinson’s disease dead? Neurosurgery. 2001;49:576–580.
79. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. 2003;54:403–414.
80. Kolata G. Parkinson’s research is set back by failure of fetal cell implants. The New York Times . March 8, 2001:1.
81. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69–73.
82. Stolberg SG. The biotech death of Jessie Gelsinger. The New York Times Magazine. November 28, 1999.
83. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4:241–248.
84. Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: Emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety. 2000;11:185–186.
85. Molina JA, Sainz-Artiga MJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-Pareja M, Bermejo F. Pathologic gambling in Parkinson’s disease: A behavioral manifestation of pharmacologic treatment? Mov Disorders. 2000;15:869–872.
86. Driver-Dunkley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology. 2003;61:422–423.
87. Bergh C, Eklund T, Sodersten P, Nordin C. Altered dopamine function in pathological gambling. Psychol Med. 1997;27:473–475.
88. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: Motor vehicle accidents in patients taking pramipexole and ropinirole. Neurology. 1999;52:1908–1910.
89. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disorders. 2003;18:659–667.
90. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: Demographic, clinical, and laboratory fi ndings in 93 cases. Brain. 2000;123:331–339.
91. Tinetti ME. Preventing falls in elderly persons. New Engl J Med. 2003;348:42–49.
92. Lauritzen JB. Hip fractures: Incidence, risk factors, energy absorption, and prevention. Bone. 1996;18:65S–75S.
93. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. New Engl J Med. 1988;319:1701–1707
94. Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M, et al. Prevention of hip fracture in elderly people with use of a hip protector. New Engl J Med. 2000;343:1506–1513.
95. Barrett A. Servants of the Map. New York: W. W. Norton; 2002:171–194.
96. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson’s disease. Ann Neurol. 2001;49:525–529.
97. EPDA Charter for People with Parkinson’s Disease. 1997. Available at: http://www.epda.eu.com/worldPDDay/worldPDDay_epdaCharter.shtm. Accessed April 1, 2006.